Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.730
-0.020 (-1.14%)
Dec 5, 2025, 4:00 PM EST - Market closed
Protalix BioTherapeutics Revenue
Protalix BioTherapeutics had revenue of $17.85M in the quarter ending September 30, 2025, a decrease of -0.60%. This brings the company's revenue in the last twelve months to $61.84M, up 35.42% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.
Revenue (ttm)
$61.84M
Revenue Growth
+35.42%
P/S Ratio
2.13
Revenue / Employee
$290,329
Employees
213
Market Cap
139.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.40M | -12.10M | -18.47% |
| Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
| Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
| Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
| Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PLX News
- 23 days ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results - PRNewsWire
- 4 weeks ago - Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - PRNewsWire
- 4 weeks ago - PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 4 weeks ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU - GlobeNewsWire
- 7 weeks ago - Why Is Protalix BioTherapeutics Stock Falling On Friday? - Benzinga
- 7 weeks ago - Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 3 months ago - Protalix BioTherapeutics to Present at Investor Summit Virtual - Accesswire